PHR Stock Analysis: Phreesia | NYSE
Health Information Services | NYSE, USA | Market Cap: 622m USD | 12M Return: -62.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.1M
Qual. Beats: 0
Rev. Trend: 99.5%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: under 40 is mostly noise, over 50 gets interesting, and over 70 is strong.
Phreesia, Inc. is a U.S.-based healthcare technology company that provides an integrated SaaS platform combining patient intake, scheduling, communications, and payment processing for healthcare organizations across the United States and Canada. Its offerings include AI-enabled appointment optimization and referral management, smart patient answering via voice and messaging, embedded payment and patient financing solutions, digital intake and clinical data capture, patient engagement tools, and analytics. The company complements its software with proprietary hardware, including the PhreesiaPad self-service intake tablet and Arrivals Kiosks, and serves ambulatory practices, health systems, hospitals, life sciences companies, and government and non-profit organizations. Phreesia was incorporated in 2005 and is headquartered in Wilmington, Delaware.
Phreesia operates within the Health Care Technology sub-industry, a segment that sells software and digital workflow tools to providers, payers, and life sciences firms. A distinguishing feature of its business model is the combination of subscription-based SaaS revenue with transaction-based payment processing fees generated as patients settle balances through the platform during intake and post-visit workflows.
- Subscription revenue accelerates on health system client expansion
- Payment processing volume rebounds with patient visit recovery
- Operating margin expansion progresses toward profitability milestone
| Net Income: 9.18m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 4.55 > 1.0 |
| NWC/Revenue: 23.24% < 20% (prev 24.09%; Δ -0.86% < -1%) |
| CFO/TA 0.13 > 3% & CFO 87.9m > Net Income 9.18m |
| Net Debt (19.8m) to EBITDA (42.4m): 0.47 < 3 |
| Current Ratio: 1.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.0m) vs 12m ago 5.30% < -2% |
| Gross Margin: 65.81% > 18% (prev 68.02%; Δ -2.21% > 0.5%) |
| Asset Turnover: 92.93% > 50% (prev 108.5%; Δ -15.59% > 0%) |
| Interest Coverage Ratio: 0.83 > 6 (EBIT TTM 7.78m / Interest Expense TTM 9.32m) |
| A: 0.17 (Total Current Assets 267.3m - Total Current Liabilities 152.1m) / Total Assets 666.1m |
| B: -1.20 (Retained Earnings -796.2m / Total Assets 666.1m) |
| C: 0.01 (EBIT TTM 7.78m / Avg Total Assets 533.3m) |
| D: 1.17 (Book Value of Equity 359.1m / Total Liabilities 307.1m) |
| Altman-Z'' = -1.44 = CCC |
| DSRI: 1.16 (Receivables 143.3m/108.1m, Revenue 495.6m/434.5m) |
| GMI: 1.03 (GM 68.02% / 65.81%) |
| AQI: 1.41 (AQ_t 0.56 / AQ_t-1 0.40) |
| SGI: 1.14 (Revenue 495.6m / 434.5m) |
| TATA: -0.12 (NI 9.18m - CFO 87.9m) / TA 666.1m) |
| Beneish M = -2.53 (Cap -4..+1) = A |
As of July 02, 2026, the stock is trading at USD 10.29 with a total of 708,232 shares traded. Over the past week, the price has changed by +11.78%, over one month by +0.56%, over three months by +27.62% and over the past year by -62.37%.
Current recommended Stop Loss: 9.20 (which is 10.6% or 2 ATR below the current price).
Phreesia has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy PHR.
- StrongBuy: 10
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13.9 | 35.5% |
P/E Trailing = 62.9375
P/E Forward = 13.4228
P/S = 1.256
P/B = 1.7334
Revenue TTM = 495.6m USD
EBIT TTM = 7.78m USD
EBITDA TTM = 42.4m USD
Long Term Debt = 85.3m USD (from longTermDebt, last quarter)
Short Term Debt = 6.36m USD (from shortTermDebt, last quarter)
Debt = 94.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.95m
Net Debt = 19.8m USD (calculated: Debt 94.5m - CCE 74.7m)
Enterprise Value = 642.2m USD (622.4m + Debt 94.5m - CCE 74.7m)
Interest Coverage Ratio = 0.83 (Ebit TTM 7.78m / Interest Expense TTM 9.32m)
EV/FCF = 8.83x (Enterprise Value 642.2m / FCF TTM 72.7m)
FCF Yield = 11.33% (FCF TTM 72.7m / Enterprise Value 642.2m)
FCF Margin = 14.68% (FCF TTM 72.7m / Revenue TTM 495.6m)
Net Margin = 1.85% (Net Income TTM 9.18m / Revenue TTM 495.6m)
Gross Margin = 65.81% ((Revenue TTM 495.6m - Cost of Revenue TTM 169.5m) / Revenue TTM)
Gross Margin QoQ = 59.21% (prev 68.21%)
Tobins Q-Ratio = 0.96 (Enterprise Value 642.2m / Total Assets 666.1m)
Interest Expense / Debt = 9.86% (Interest Expense 9.32m / Debt 94.5m)
Taxrate = 37.26% (1.76m / 4.72m)
NOPAT = 4.88m (EBIT 7.78m * (1 - 37.26%))
Current Ratio = 1.76 (Total Current Assets 267.3m / Total Current Liabilities 152.1m)
Debt / Equity = 0.26 (Debt 94.5m / totalStockholderEquity, last quarter 359.1m)
Debt / EBITDA = 0.47 (Net Debt 19.8m / EBITDA 42.4m)
Debt / FCF = 0.27 (Net Debt 19.8m / FCF TTM 72.7m)
Total Stockholder Equity = 328.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.72% (Net Income 9.18m / Total Assets 666.1m)
RoE = 2.79% (Net Income TTM 9.18m / Total Stockholder Equity 328.7m)
RoCE = 1.88% (EBIT 7.78m / Capital Employed (Equity 328.7m + L.T.Debt 85.3m))
RoIC = 0.98% (NOPAT 4.88m / Invested Capital 495.6m)
WACC = 11.21% (E(622.4m)/V(717.0m) * Re(11.97%) + D(94.5m)/V(717.0m) * Rd(9.86%) * (1-Tc(0.37)))
Discount Rate = 11.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 5.88%
[DCF] Terminal Value 69.30% ; FCFF base≈53.8m ; Y1≈61.7m ; Y5≈90.8m
[DCF] Fair Price = 14.35 (EV 907.0m - Net Debt 19.8m = Equity 887.2m / Shares 61.8m; r=11.21% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.48 | # QB: 0
Revenue Correlation: 99.51 | Revenue CAGR: 16.84% | SUE: 3.22 | # QB: 1
EPS current Quarter (2026-07-31): EPS=0.32 | Chg30d=+3.10% | Revisions=+17% | Analysts=10
EPS next Quarter (2026-10-31): EPS=0.35 | Chg30d=-5.61% | Revisions=-38% | Analysts=9
EPS current Year (2027-01-31): EPS=1.33 | Chg30d=-4.10% | Revisions=-33% | GrowthEPS=+2.9% | GrowthRev=+7.2%
EPS next Year (2028-01-31): EPS=1.61 | Chg30d=-4.52% | Revisions=-8% | GrowthEPS=+20.8% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: -38%